Clinical trial
Phase 1/2 Investigation of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (Pioneer-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002
NCT07287397 is registered in ClinicalTrials.gov with Vector Y Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2 Investigation of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (Pioneer-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002
- Lead sponsor
- Vector Y Therapeutics
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- December 19, 2025
- Completion date
- October 15, 2027
- Enrollment
- 12 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.